# Alfred L. Garfall

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alfred-l-garfall/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,527 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 42 |
| i10-index | 102 |
| Last Known Institution | Hospital of the University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5035811221 |
| ORCID iD | 0000-0003-2791-5748 |
| Works | 315 |

## Researcher papers

- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma](https://scholariq.org/papers/ny-eso-1-specific-tcr-engineered-t-cells-mediate-sustained-antigen-specific/)
- [Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients](https://scholariq.org/papers/lectin-type-oxidized-ldl-receptor-1-distinguishes-population-of-human/)
- [B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma](https://scholariq.org/papers/b-cell-maturation-antigen-specific-car-t-cells-are-clinically-active-in-multiple/)
- [IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion](https://scholariq.org/papers/il-4-induces-cathepsin-protease-activity-in-tumor-associated-macrophages-to/)
- [Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma](https://scholariq.org/papers/chimeric-antigen-receptor-t-cells-against-cd19-for-multiple-myeloma/)
- [Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer](https://scholariq.org/papers/macrophages-and-cathepsin-proteases-blunt-chemotherapeutic-response-in-breast/)
- [CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer](https://scholariq.org/papers/cd8-t-cells-contribute-to-survival-in-patients-with-covid-19-and-hematologic/)
- [Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer](https://scholariq.org/papers/origin-and-role-of-a-subset-of-tumor-associated-neutrophils-with-antigen/)
- [Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study](https://scholariq.org/papers/teclistamab-a-b-cell-maturation-antigen-cd3-bispecific-antibody-in-patients-with/)
- [Factors Related to Long-Term Caregiving Burden Among Chimeric Antigen Receptor (CAR) T-Cell Recipients and Their Informal Caregivers](https://scholariq.org/papers/factors-related-to-long-term-caregiving-burden-among-chimeric-antigen-receptor/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [Hospital of the University of Pennsylvania](https://scholariq.org/institutions/hospital-of-the-university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.